2016 Fiscal Year Final Research Report
Development of novel therapeutics for Parkinson disease by FABP3 ligands
| Project/Area Number |
15H06036
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Pharmacology in pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-08-28 – 2017-03-31
|
| Keywords | パーキンソン病 / α-シヌクレイン / FABP3 |
|---|
| Outline of Final Research Achievements |
α-synuclein is one of major components in lewy bodies and its aggregates promotes neurodegeneration and cell death in dopaminergic neurons, thereby triggering Parkinson disease. Fatty acid binding protein 3 (FABP3) aggravates MPTP-induced α-synuclein oligomerizations in mouse dopaminergic neurons. In the present study, we investigated whether FABP3 ligands prevent α-synuclein oligomerizations and motor impairments in Parkinson models. In vitro assay, FABP3 ligands significantly inhibited MPP+-induced α-synuclein oligomerizations in both α-synuclein and FABP3 over-expressed PC12 cells. In addition, oral administration of FABP3 ligands significantly prevented α-synuclein oligomerizations and cell death in dopaminergic neurons in the substantia nigra, thereby improving motor impairments seen in animal model of Parkinson disease. Taken together, those results suggest that FABP3 ligands may be attractive candidate of novel therapeutics for Parkinson disease.
|
| Free Research Field |
神経薬理学
|
